

**Alfredo PIZZUTI**

SC Cardiologia  
AO Ordine Mauriziano  
Torino



TURIN  
October  
24<sup>th</sup>-26<sup>th</sup>  
2019

# 31 GIORNATE CARDIOLOGICHE TORINESI

---


*Everything you always  
wanted to know about  
Hypertrophic Cardiomyopathy*



# *Hypertrophic Cardiomyopathy*

## HCM-related mortality

percent per year



# *Hypertrophic Cardiomyopathy*

## **Risk factors for Sudden Death**

- **Age**
- **Family history of Sudden Death (SD)**
- **Unexplained Syncope**
- **Left Ventricular wall thickness**
- **Left Ventricular outflow gradient**
- **Non Sustained Ventricular Tachycardia**



# *Hypertrophic Cardiomyopathy*

## **Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors**

Paolo Spirito, MD<sup>a,\*</sup>, Camillo Autore, MD<sup>b</sup>, Francesco Formisano, MD<sup>a</sup>, Gabriele Egidy Assenza, MD<sup>b</sup>, Elena Biagini, MD<sup>c</sup>, Tammy S. Haas, RN<sup>d</sup>, Sergio Bongioanni, MD<sup>e</sup>, Christopher Semsarian, MD<sup>f</sup>, Emmanuela Devoto, MD<sup>a</sup>, Beatrice Musumeci, MD<sup>b</sup>, Francesco Lai, MD<sup>c</sup>, Laura Yeates, BSc<sup>f</sup>, Maria Rosa Conte, MD<sup>e</sup>, Claudio Rapezzi, MD<sup>c</sup>, Luca Boni, MD<sup>g</sup>, and Barry J. Maron, MD<sup>d</sup>

- **absence of each of the conventional major sudden death risk factors**

- NYHA I or II N = 653; f-u 5.3 y
- No Atrial Fibrillation **SD: 0.6% per year**
- No myectomy, septal ablation or ICD implant
- LVEF >50%
- Age ≥10 and ≤75 years



# Hypertrophic Cardiomyopathy


## Risk of Sudden Death and Outcome in Patients With Hypertrophic Cardiomyopathy With Benign Presentation and Without Risk Factors

Paolo Spirito, MD<sup>a,\*</sup>, Camillo Autore, MD<sup>b</sup>, Francesco Formisano, MD<sup>a</sup>, Gabriele Egidy Assenza, MD<sup>b</sup>, Elena Biagini, MD<sup>c</sup>, Tammy S. Haas, RN<sup>d</sup>, Sergio Bongioanni, MD<sup>e</sup>, Christopher Semsarian, MD<sup>f</sup>, Emmanuela Devoto, MD<sup>a</sup>, Beatrice Musumeci, MD<sup>b</sup>, Francesco Lai, MD<sup>c</sup>, Laura Yeates, BSc<sup>f</sup>, Maria Rosa Conte, MD<sup>e</sup>, Claudio Rapezzi, MD<sup>c</sup>, Luca Boni, MD<sup>g</sup>, and Barry J. Maron, MD<sup>d</sup>

	Relative Risk (95% IC)	<i>p</i>
Age	0.97 (0.94–0.99)	<b>0.020</b>
Sex	-	0.43
Left Ventricular Outflow Obstruction	-	0.822
Wall thickness	-	0.646
<b>Left Atrial diameter (mm):</b>		
< 41	1	
41 - 50	3.11 (1.13-8.54)	<b>0.009</b>
> 50	8.01 (2.08-30.9)	



# Hypertrophic Cardiomyopathy




# Hypertrophic Cardiomyopathy



European Heart Journal (2014) 35, 2733–2779  
doi:10.1093/eurheartj/ehu284

ESC GUIDELINES

## 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy




# Hypertrophic Cardiomyopathy

## Probability of Sudden Death at 5 years

$$P=1 - 0.998^{\text{exp(Prognostic Index)}}$$

- 0.1593 \* Maximal Wall Thickness (mm)
- 0.0029 \* MWT<sup>2</sup> (mm<sup>2</sup>)
- + 0.0259 \* Left Atrial Dimension (mm)
- + 0.0044 \* Outflow gradient (mmHg)
- + 0.4583 \* Family History of SD
- + 0.8263 \* NSVT
- + 0.7165 \* Syncope
- 0.0179 \* Age (years)

= Prognostic Index





# Hypertrophic Cardiomyopathy

## Probability of Sudden Death at 5 years

$$P=1 - 0.998^{\text{exp(Prognostic Index)}}$$

$$\begin{aligned} & 0.1593 * \text{Maximal Wall Thickness (mm)} \\ - & 0.0029 * \text{MWT}^2 \text{ (mm}^2\text{)} \\ + & 0.0259 * \text{Left Atrial Dimension (mm)} \\ + & 0.0044 * \text{Outflow gradient (mmHg)} \\ + & 0.4583 * \text{Family History of SD} \\ + & 0.8263 * \text{NSVT} \\ + & 0.7165 * \text{Syncope} \\ - & 0.0179 * \text{Age (years)} \end{aligned}$$

---


= Prognostic Index

*However, when applied to individual patients with HCM, the risk score has **low sensitivity** for making clinically relevant decisions about implantable cardioverter-defibrillator (ICD) placement, significantly underidentifying high-risk patients*


*Maron BJ, N Engl J Med 2018; 379:655*



# Hypertrophic Cardiomyopathy




# Apical Aneurysm in *Hypertrophic Cardiomyopathy*



# Hypertrophic Cardiomyopathy

## Prevalence, Clinical Significance, and Natural History of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy

Martin S. Maron, MD; John J. Finley, MD; J. Martijn Bos, MD;



**3 patients out of 7 without any risk factors for Sudden Death**






# Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm


## Implications for Risk Stratification and Management

Ethan J. Rowin, MD,<sup>a</sup> Barry J. Maron, MD,<sup>a</sup> Tammy S. Haas, RN,<sup>b</sup> Ross F. Garberich, MS,<sup>b</sup> Weijia Wang, MD, Mark S. Link, MD,<sup>a</sup> Martin S. Maron, MD<sup>a</sup>



# Hypertrophic Cardiomyopathy

## Event rate **with** or **without** apical aneurysm




# Phenotypic overlap in hypertrophic cardiomyopathy: Apical hypertrophy, midventricular obstruction, and apical aneurysm


Yuichiro Minami (MD)\*, Shintaro Haruki (MD), Nobuhisa Hagiwara (MD, FJCC)

Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan

## Probability of Sudden Death / Lethal arrhythmias



# Apical Aneurysm in *Hypertrophic Cardiomyopathy*



8 years later






The ventricular myocardium, both right and left, exists as a continuous muscle band

**Myofibers orientation**


**Red: clockwise**

**Green: counterclockwise**

**Blue: Circular**



Diffusion Tensor Magnetic Resonance Imaging (DTMRI)



PubMed  [Create RSS](#) [Create alert](#) [Advanced](#)

Format: Summary

### Search results

Items: 1 to 20 of 14431

PubMed  [Create RSS](#) [Create alert](#) [Advanced](#)

Format: Summary

[Send to](#)

### Search results

Items: 1 to 20 of 39

<< First < Prev Page 1 of 2 Next > Last

PubMed  [Create RSS](#) [Create alert](#) [Advanced](#)

Format: Summary

[Send to](#)

### Search results

Items: 1 to 20 of 33

<< First < Prev Page 1 of 2 Next > Last >>





## *Right Ventricular Hypertrophy in Hypertrophic Cardiomyopathy*

<i>Autor</i>	<i>year</i>	<i>N° of patients</i>	<i>Patients with RVH</i>	<i>notes</i>
<b>McKenna</b>	1988	73	<b>44%</b>	Echo ≥6 mm
<b>Roşca</b>	2015	99	<b>53%</b>	Echo >5mm
<b>Maron</b>	2007	46	<b>33%</b>	CMR 2SD>5±1 mm
<b>Nagata</b>	2015	106	<b>28%</b>	CMR >5 mm
<b>Our cases Merello</b>	2019	61	<b>38% RV free wall 62% other RV structures</b>	CMR ≥5 mm



# Hypertrophic Cardiomyopathy


## Hypertrophic structures of the Right Ventricle



# Hypertrophic Cardiomyopathy



## Hypertrophic Moderator Band

15/09/2019 16:29:33  
ACE



# Hypertrophic Cardiomyopathy


## Flow turbulence and gradient at level of the Hypertrophic Moderator Band





**B.A.**

**Loop-Recorder:**



# Right Ventricular Remodeling, Its Correlates, and Its Clinical Impact in Hypertrophic Cardiomyopathy


**Table 5** Correlates of ventricular arrhythmia in patients with HCM (N=99)

Variables	Univariate analysis			Multivariate analysis
	OR	95% CI	P	P
Age	0.973	0.942–1.006	.10	.25
LAVi	0.996	0.974–1.019	.75	—
Septal S	0.891	0.632–1.255	.50	—
Lateral S	0.782	0.536–1.142	.20	—
Mean e'	0.899	0.662–1.222	.49	—
E/e' ratio	0.970	0.881–1.069	.53	—
LVMi	1.003	0.995–1.012	.45	—
LVWT	1.166	1.039–1.308	.009	.17
LV GLS	1.182	0.996–1.402	.05	.35
<b>RVWT (N=52)</b>	<b>1.850</b>	<b>1.314–2.605</b>	<b>&lt;.001</b>	<b>.002</b>
RV S velocity	0.902	0.730–1.113	.33	—
RV GLS	1.069	0.936–1.221	.32	—
RVW <sub>ε</sub>	1.014	0.915–1.124	.78	—
sPAP	0.980	0.925–1.038	.48	—
LV outflow tract gradient	1.000	0.971–1.030	.98	—
MR degree	0.900	0.493–1.643	.73	—





**Right Ventricular Hypertrophy** Is Associated With Cardiovascular Events in **Hypertrophic Cardiomyopathy**: Evidence From Study With Magnetic Resonance Imaging



(hazard ratio, 5.42; 95% IC, 1.16-25.3)



# *Hypertrophic Cardiomyopathy*

Take  message

- Measure Left Atrium
- Look for apical aneurysm and follow it up
- Check the right ventricle

Thank you

